Navigation Links
Ophthalmology highlights Jan. 2009
Date:1/5/2009

SAN FRANCISCO, CA---With a new study from the Centers for Disease Control and Prevention predicting that diabetic retinopathy will triple from 5.5 million in 2005 to 16 million in 2050, improved treatments are urgently needed for this leading cause of blindness in working-age people. The CDC study is the latest indicator of a world-wide diabetes epidemic that is motivating ophthalmic research around the globe. Hideharu Funatsu, MD, and colleagues at the Tokyo Women's Medical University, Japan, focused on diabetic macular edema (DME) a serious complication of retinopathy. Their findings on inflammatory factors associated with DME are presented in this month's Ophthalmology, the journal of the American Academy of Ophthalmology.

Retinopathy typically develops gradually over many years in people who have diabetes. It impacts the retina, the area at the back of the eye that focuses images for transmission to the brain. Advanced complications include the growth of abnormal blood vessels on the retina and optic nerve, and DME, swelling of the macula at the center of the retina as fluid leaks from permeable blood vessels. Precisely how DME develops is unclear, but the condition is similar to chronic inflammation that can occur in other areas of the body. When inflammation occurs, the body's immune system releases chemical messengers into the blood or affected tissues in an attempt to rid the body of a perceived infection, irritant, or injury. Some of the chemicals cause leakage of fluid into the tissues, resulting in swelling.

Dr. Funatsu's group measured levels of four inflammatory factors and one anti-inflammatory factor in the vitreous gel, which fills the eye between the lens and the retina, in 53 patients with DME, 15 patients with nondiabetic ocular disease, and 8 diabetic patients without retinopathy. Vascular endothelial growth factor (VEGF), intercellular adhesion molecule (ICAM)-1, interleukin (IL)-6, monocyte chemotactic protein (MCP)-1 and the anti-inflammatory pigment epithelium-derived factor (PEDF) were selected because earlier research had linked them to the development or exacerbation of DME.

All four inflammatory factors were significantly higher and PEDF significantly lower in the vitreous of in patients with DME compared with the two other patient groups. VEGF and ICAM-1 had a stronger influence on the severity of DME than the other factors. VEGF is a strong vascular permeability factor that is overproduced in response to reduced oxygen levels in the retinas of people with retinopathy, and Dr. Funatsu's research suggests that VEFG is the key to the inflammatory response in DME. Building on earlier, similar findings, the study also indicates that PEDF may block the expression and actions of the key inflammatory factors.

Although this study suggests that intravitreal injection of steroids such as triamcinolone acetonide may be useful in treating DME, further clinical trials are required to confirm this finding.

"Triamcinolone acetonide down-regulates VEGF and ICAM-1, inhibits inflammatory cells, stabilizes cell membranes, and increases PEDF levels. It appears to control more of the cytokine messengers that contribute to abnormal blood vessel permeability," said Dr. Funatsu. He adds that further focus on VEGF and ICAM-1 may further illuminate the mechanisms of blood vessel breakdown in DME and lead to new treatments.


'/>"/>

Contact: Mary Wade
mwade@aao.org
415-447-0221
American Academy of Ophthalmology
Source:Eurekalert

Related medicine news :

1. Lumenis(R) Introduces Four New Products & Delivery Devices at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, Georgia USA
2. Long-Term Results of VisionCares Implantable Telescope for End-Stage Macular Degeneration Published in the American Journal of Ophthalmology
3. Second Annual Eye Ball Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology
4. The Most Ordinary Things Can Cause the Most Extraordinary Eye Injuries, Says the Oklahoma Academy of Ophthalmology
5. September Ophthalmology research highlights
6. Highlights from the August 2008 issue of Ophthalmology
7. Mergent, Inc. Announces Changes to the HealthShares(TM) Ophthalmology Index
8. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting
9. American Academy of Ophthalmology Mourns Loss of Judah Folkman, MD, Pioneering Researcher
10. University Hospitals Case Medical Center Ophthalmology gets grant for vision-threatening conditions
11. Angiotech To Participate In The American Academy Of Ophthalmology (AAO) 2007 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Somerset, N.J. (PRWEB) , ... May 26, 2016 ... ... advanced delivery technologies and development solutions for drugs, biologics, consumer health and global ... new sales office in Korea to support the company’s continued investment and strategic ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... In an effort to provide hair restoration ... to both Snapchat users and those who do not use the app. Dr. Mohebi, the ... new page, Dr. Mohebi Live . , Dr. Mohebi says, “The positive response ...
(Date:5/26/2016)... ... May 26, 2016 , ... Eating Recovery ... disorders, is opening a brand new child and adolescent residential treatment center on ... families with even more specialized eating disorder treatment and access to life-saving care. ...
(Date:5/26/2016)... ... May 26, 2016 , ... Nike Yoga Camps at East ... practices, arts & crafts, discussions, and games all geared towards enhancing your child’s ... combined backgrounds in kids’ yoga, collegiate sport yoga instruction, and global yoga training. ...
(Date:5/26/2016)... Scotch Plains, NJ (PRWEB) , ... May 26, ... ... year being recognized as an NJ Top Doc! Along with his wonderful accolades ... to excellence in podiatry. Congratulations, Dr. Batelli! , Dr. Eugene Batelli is ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 2016 TARE (Transarterial Radio-embolization) ... Savings and Overall Decreased Use of Hospital ... international specialist healthcare company, has today announced the ... Meeting of ISPOR (International Society for Pharmacoeconomics and ... (HCC) using yttrium-90 glass microspheres is associated with ...
(Date:5/25/2016)... und GERMANTOWN, Maryland , May ... mit Therawis bedient dringenden ... QIAGEN N.V. (NASDAQ: QGEN ... eine Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH ... Onkologie eingegangen zu sein. Ein erstes Projekt wird ...
(Date:5/25/2016)... As illustrated by the Spring ... the numbers and momentum of cannabis in the US ... billions, more research and development push the sector forward. ... Legal Marijuana Markets Report  from from ArcView Market Research ... the increase in sector is attributed to adult use ...
Breaking Medicine Technology: